Universal Implementation of Newborn Screening in India
Newborn screening is a successful program in many developed countries. In India, the benefits of dried blood spot screening have been recognized and that screening is slowly gaining traction. There are significant issues standing in the way of universal implementation of a newborn screening program...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | International Journal of Neonatal Screening |
Subjects: | |
Online Access: | https://www.mdpi.com/2409-515X/6/2/24 |
id |
doaj-606f2498e7ae492db6e9a26a6a3dd694 |
---|---|
record_format |
Article |
spelling |
doaj-606f2498e7ae492db6e9a26a6a3dd6942020-11-25T02:10:02ZengMDPI AGInternational Journal of Neonatal Screening2409-515X2020-03-01622410.3390/ijns6020024ijns6020024Universal Implementation of Newborn Screening in IndiaThomas Mookken0NeoGen Labs, UCF Center, 84/3 Oil Mill Road, Lingararajpuram, Bengaluru 560 084, Karnataka, IndiaNewborn screening is a successful program in many developed countries. In India, the benefits of dried blood spot screening have been recognized and that screening is slowly gaining traction. There are significant issues standing in the way of universal implementation of a newborn screening program in India: awareness, cost, advocacy, public policy, and politics. Three regional screening programs, Chandigarh, Goa, and Kerala could serve as models for other programs in India. The data for this commentary were based on personal experiences from managing public newborn screening programs, searches on PubMed and Google, and personal interactions with experts in the field. The overwhelming recommendation is to universally screen for congenital hypothyroidism in India, because it is easy and inexpensive to treat, with excellent outcomes. It would also be beneficial to consider screening universally for glucose-6-phosphate dehydrogenase deficiency due to its high incidence and ease of treatment. Finally, sickle cell disease should be screened in those areas in India where it is prevalent due to the costs associated with universal screening. Achieving universal screening is a challenge, and it is very difficult to predict when every baby born in India will be screened for at least congenital hypothyroidism.https://www.mdpi.com/2409-515X/6/2/24inborn errors of metabolismneonatalnewborn screeningpopulation screeningsickle cell disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thomas Mookken |
spellingShingle |
Thomas Mookken Universal Implementation of Newborn Screening in India International Journal of Neonatal Screening inborn errors of metabolism neonatal newborn screening population screening sickle cell disease |
author_facet |
Thomas Mookken |
author_sort |
Thomas Mookken |
title |
Universal Implementation of Newborn Screening in India |
title_short |
Universal Implementation of Newborn Screening in India |
title_full |
Universal Implementation of Newborn Screening in India |
title_fullStr |
Universal Implementation of Newborn Screening in India |
title_full_unstemmed |
Universal Implementation of Newborn Screening in India |
title_sort |
universal implementation of newborn screening in india |
publisher |
MDPI AG |
series |
International Journal of Neonatal Screening |
issn |
2409-515X |
publishDate |
2020-03-01 |
description |
Newborn screening is a successful program in many developed countries. In India, the benefits of dried blood spot screening have been recognized and that screening is slowly gaining traction. There are significant issues standing in the way of universal implementation of a newborn screening program in India: awareness, cost, advocacy, public policy, and politics. Three regional screening programs, Chandigarh, Goa, and Kerala could serve as models for other programs in India. The data for this commentary were based on personal experiences from managing public newborn screening programs, searches on PubMed and Google, and personal interactions with experts in the field. The overwhelming recommendation is to universally screen for congenital hypothyroidism in India, because it is easy and inexpensive to treat, with excellent outcomes. It would also be beneficial to consider screening universally for glucose-6-phosphate dehydrogenase deficiency due to its high incidence and ease of treatment. Finally, sickle cell disease should be screened in those areas in India where it is prevalent due to the costs associated with universal screening. Achieving universal screening is a challenge, and it is very difficult to predict when every baby born in India will be screened for at least congenital hypothyroidism. |
topic |
inborn errors of metabolism neonatal newborn screening population screening sickle cell disease |
url |
https://www.mdpi.com/2409-515X/6/2/24 |
work_keys_str_mv |
AT thomasmookken universalimplementationofnewbornscreeninginindia |
_version_ |
1724921065352724480 |